Bacteriological results and leprosy reactions among MB leprosy patients treated with Uniform Multidrug Therapy in China

Shen, Jianping; Nagaraju, Bathyala; Kroeger, Axel; Arana, Byron; Pannikar, Vijay; Hongjiang, Mou; Bao, Xia; Yang, Rongde; Ponnaiah, Manickam; Li, Wenzhong; Zhou, Min; Want, Juan

doi:10.47276/lr.83.2.164

Cited by 13 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two study sites carried out skin smear test as part of their implementing agency's or country's policy and practice although skin smear examination was not required as per common protocol. P. R. China sites performed skin smear examination and documented rapid fall in bacteriological index with almost 95 per cent MB patients becoming smear negative at the end of five years of follow up 37 38 . This information further supports the applicability of U-MDT in the programme.…”

Section: Discussionmentioning

confidence: 99%

International open trial of uniform multidrug therapy regimen for leprosy patients

Ponnaiah

Mehendale

Nagaraju

et al. 2016

Indian Journal of Medical Research

View full text Add to dashboard Cite

Background & objectives: Uniform therapy for all leprosy patients will simplify leprosy treatment. In this context, we evaluated six-month multidrug therapy (MDT) currently recommended for multibacillary (MB) patients as uniform MDT (U-MDT) in a single-arm open trial under programme conditions. Primary objective was to determine efficacy to prevent five-year cumulative five per cent relapse. Secondary objectives were to assess acceptability, safety and compliance. Methods: Newly detected, treatment-naive leprosy patients were enrolled in India (six sites) and P. R. China (two sites). Primary outcome was clinically confirmed relapse of occurrence of one or more new skin patches consistent with leprosy, without evidence of reactions post-treatment. Event rates per 100 person years as well as five-year cumulative risk of relapse, were calculated. Results: A total of 2091 paucibacillary (PB) and 1298 MB leprosy patients were recruited from the 3437 patients screened. Among PB, two relapsed (rate=0.023; risk=0.11%), eight had suspected adverse drug reactions (ADRs) (rate=0.79) and rate of new lesions due toreactions was 0.24 (n=23). Rates of neuritis, type 1 and type 2 reactions were 0.39 (n=37), 0.54 (n=51) and 0.03 (n=3), respectively. Among MB, four relapsed (rate=0.07; risk=0.37%) and 16 had suspected ADR (rate=2.64). Rate of new lesions due to reactions among MB was 1.34 (n=76) and rates of neuritis, type 1 and type 2 reactions were 1.37 (n=78), 2.01 (n=114) and 0.49 (n=28), respectively. Compliance to U-MDT was 99 per cent. Skin pigmentation due to clofazimine was of short duration and acceptable. Interpretation & conclusions: We observed low relapse, minimal ADR and other adverse clinical events. Clofazimine-related pigmentation was acceptable. Evidence supports introduction of U-MDT in national leprosy programmes. [CTRI No: 2012/ 05/ 002696]

show abstract

Section: Discussionmentioning

confidence: 99%

International open trial of uniform multidrug therapy regimen for leprosy patients

Ponnaiah

Mehendale

Nagaraju

et al. 2016

Indian Journal of Medical Research

View full text Add to dashboard Cite

show abstract

“…The result found signifi cant reduc• on of BI and 73.5% of pa• ents were declared to be nega• ve BI, 13 pa• ents (14.6%) had leprosy reac• on, and one pa• ent had a relapse. 20 Subsequent follow-up was done at 6 years a• er treatment comple• on with U-MDT and there were 98.7% of pa• ents with nega• ve BI. The authors concluded that U-MDT can quickly reduce the bacilli ac• vity, reduced the BI permanently, produce low relapse rate, and acceptable rate of leprosy reac• on.…”

Section: Studies For the Effectivity Of U-mdt For The Treatment Of Pb...mentioning

confidence: 99%

Effectivity of Uniform Multidrug Therapy on the Success of Paucibacillary and Multibacillary Leprosy Treatment

Susanto¹,

Esti²,

Komarasari³

2022

Nepal J Dermatol Venereol & Leprol

View full text Add to dashboard Cite

Leprosy is a chronic infectious disease caused by Mycobacterium leprae (M. leprae) that involves the integumentary and peripheral nervous system, causing neuropathy, deformity, and disability. Early detection and appropriate treatment are the ways to break the chain of transmission and prevent disability in leprosy patients. The first line of treatment for leprosy is the standard Multidrug Therapy (MDT) regiment consisting of rifampicin, dapsone, and clofazimine. Standard MDT treatment is given based on the leprosy classification of paucibacillary (PB) and multibacillary (MB). The utilization of the standard MDT regiment has some limitations, particularly where there is a limited supporting test facility, causing difficulty in determining the leprosy classification accurately. An alternative regiment proposed to substitute the standard MDT is the Uniform-MDT (U-MDT). Several studies have been conducted on the use of U-MDT and have produced promising results for the treatment of PB and MB leprosy.

show abstract

“…Another study found a 6-month regimen associated with a trend towards worse clinical outcomes compared with a 12-month regimen (good clinical response at 24 months 25% vs 77%, RR 0.33, 95% CI: 0.06-1.8) (63). Several uncontrolled studies were included in the evidence review, but provided very limited data on relapses and clinical outcomes (61,70,71). Results regarding side-effects of and compliance with a shorter MB leprosy regimen seem to be encouraging, though data were scarce.…”

Section: Summary Of the Evidencementioning

confidence: 99%

PANLAR Abstracts 2021

Missing¹

2021

J Clin Rheumatol

View full text Add to dashboard Cite

show abstract

Bacteriological results and leprosy reactions among MB leprosy patients treated with Uniform Multidrug Therapy in China

Cited by 13 publications

References 9 publications

International open trial of uniform multidrug therapy regimen for leprosy patients

International open trial of uniform multidrug therapy regimen for leprosy patients

Effectivity of Uniform Multidrug Therapy on the Success of Paucibacillary and Multibacillary Leprosy Treatment

PANLAR Abstracts 2021

Contact Info

Product

Resources

About